Tempest Therapeutics (TPST) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TPST Tempest Therapeutics

Watchlist

0.894
-0.004-0.46%

Trading Nov 21 15:24 ET

39.03MMarket Cap-584P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Tempest Therapeutics Is Maintained at Overweight by Piper Sandler
Dow JonesNov 13 12:00 ET · Ratings
Piper Sandler Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Cuts Target Price to $5
Moomoo NewsNov 13 08:31 ET · Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
TipRanksNov 13 07:32 ET · Ratings
Scotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
TipRanksNov 13 07:30 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
BenzingaNov 13 07:25 ET
Tempest Therapeutics Analyst Ratings
BenzingaNov 13 07:24 ET · Ratings

Comments

CommonCentsVet

Nov 19 06:56

$Tempest Therapeutics (TPST.US)$ Hey good morning guys and gals. I am definitely 100% on board with this I believe it has a lot of potential but but but but. Keep in mind it's got a reverse split coming for 1/2 or 1/15 I sold half to have plenty of ammunition to buy in when it dips. I'm looking for ¢ .70 or under. I don't see this is a bad thing. NFA Just my two pennies worth.

74483586

Nov 15 14:04

$Tempest Therapeutics (TPST.US)$ if you would like to gamble on this kind of growth company, you must be well prepared for the dip and loss or holding for the long term. Complaining doesn't help.

Teddy123

Nov 13 06:24

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

$Tempest Therapeutics (TPST.US)$
13/11/2024 - 05:21
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC
Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial
Received final funding approval from NCI to move TPST-1495 into a Phas...

小竜

Nov 12 09:38

$Tempest Therapeutics (TPST.US)$

Teddy123

Nov 12 07:31

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

$Tempest Therapeutics (TPST.US)$
12/11/2024 - 21:00
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received a “Study May Proceed” letter fro...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

TPST Tempest Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target